Haya治疗技术公司购买了65M美元,用于推进心脏衰竭药物和扩大RNA研究。 Haya Therapeutics secures $65M to advance heart failure drug and expand RNA research.

Haya治疗公司是一家生物技术公司,主要从事以RNA为指南的各种疾病治疗,已获得6 500万美元的资金。 Haya Therapeutics, a biotech company focusing on RNA-guided treatments for various diseases, has secured $65 million in funding. 这项投资将有助于推动一种针对心脏衰竭的药物,并扩大对长期不编码的RNA的研究,后者是基因表达方式所涉及的基因组的一部分。 The investment will help advance a drug targeting heart failure and expand research on long non-coding RNAs, parts of the genome involved in gene expression. 该公司的目标是利用这笔资金开始人类试验其主要药物HTX-001,该药物针对一种被称为纤维化的心脏衰竭。 The company aims to use this funding to start human trials for their lead drug, HTX-001, which targets a type of heart failure known as fibrosis.